Silica-based EGFR-degrading nano-PROTACs for efficient therapy of non-small cell lung cancer
European Journal of Pharmaceutics and Biopharmaceutics · 2025-05 · 210 · 114699
DOI: 10.1016/j.ejpb.2025.114699 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2025-05. Verfasst von Lei Fang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Silicon Dioxide, ErbB Receptors, Lung Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Proteolysis targeting chimeras (PROTACs) technology is a promising strategy for degrading proteins of interest. Traditional PROTACs, however, often face challenges such as poor solubility, low stability, and off-target toxicity. To address these challenges, we integrated nanotechnology to enhance the delivery of target-protein degraders to the tumor sites, thereby improving their properties. Here, we report silica-based nano-PROTACs (SiPROTACs) that feature multiple ligands on the surface to target and degrade the transmembrane protein epidermal growth factor receptor (EGFR). SiPROTACs, with a diameter of approximately 50 nm, can efficiently bind to EGFR, recruit cereblon (CRBN) to induce EGFR ubiquitination, and facilitate their degradation by proteasomes. In HCC-827 and PC-9 cell lines, SiPROTACs initiated EGFR degradation at a notably low concentration of 50 nM, demonstrating greater efficiency compared to traditional PROTACs. In HCC-827 xenograft tumor-bearing mice, SiPROTACs accumulated at tumor site for at least 48 h and exhibited significant anti-tumor effects in vivo without causing noticeable side effects. These findings suggest a novel approach for the application of PROTACs highlighting their therapeutic potential for the treatment of non-small cell lung cancer (NSCLC).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Departement of Pharmacy, Tongren Polytechnic College, Tongren 554300, China. Electronic address: xiangma@hu…
- School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Departement of Pharmacy, Tongren Polytechnic College, Tongren 554300, China; Institute of the Higher Educat…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Fang, L., Zhu, R., Li, M., Ma, J., Fan, S., He, X., Yang, Z., Yan, Y., Ma, X., & Xiang, G. (2025). Silica-based EGFR-degrading nano-PROTACs for efficient therapy of non-small cell lung cancer. European Journal of Pharmaceutics and Biopharmaceutics, 210, 114699. https://doi.org/10.1016/j.ejpb.2025.114699
Vancouver
Fang L, Zhu R, Li M, Ma J, Fan S, He X, et al. Silica-based EGFR-degrading nano-PROTACs for efficient therapy of non-small cell lung cancer. European Journal of Pharmaceutics and Biopharmaceutics. 2025;210:114699. doi:10.1016/j.ejpb.2025.114699
BibTeX
@article{Fang2025,
author = {Fang, Lei and Zhu, Ruixue and Li, Meijing and Ma, Junhui and Fan, Sijun and He, Xuelian and Yang, Zhongrui and Yan, Yakai and Ma, Xiang and Xiang, Guangya},
title = {Silica-based EGFR-degrading nano-PROTACs for efficient therapy of non-small cell lung cancer},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2025},
volume = {210},
pages = {114699},
doi = {10.1016/j.ejpb.2025.114699}
}
EUVIMED